GLP-1 drugs can offer profitable treatment of people with osteoarthritis and knee obesity

The new study conducted by researchers from Mass General Brigham states that the addition of new drugs for slimming GLP-1 semaglutide and tirzepatid to ordinary care is a profitable treatment strategy for people with osteoarthritis and knee obesity, with tirrzeepatide, with a lower health benefit with lower costs compared to the semaglutin. Research occurs when patients and service providers try to balance the benefits of weight loss and soothe pain in relation to the costs of these new measures. The results are published in.

Weight loss can alleviate the pain of the joint, but Semglutide And the girl is expensive, and most insurance plans do not include slimming drugs. This means that many patients cannot afford these drugs. Therefore, formal economic analysis is valuable. It gives payers and decision -makers data needed to make informed decisions regarding insurance and improving access to these slimming procedures. Our goal is to ensure that payers and decision -makers had evidence they need to make conscious insurance decisions. “

Dr. Elena Losin, Elderly author, Orthopedic Surgery Department, Brigham and Women’s Hospital

The study was financed by the Arthritis Foundation and the National Institute of Arthritis, Musculoszkielet and skin diseases. Researchers used Oapol, an approved and broadly published model of computer simulation, to analyze the profitability comparing two GLP-1 drugs, as well as two other joint weight loss interventions: bariatric surgery and lifestyle modifications. They discovered that the girls offered a slightly better value than semaglutide and would be the preferred option between two drugs for most patients. For qualifying and willing patients, bariatric surgery, which provides lasting benefits, can be the best option from a clinical and economic perspective.

Restrictions on this analysis include relying on data integrated with many sources. In addition, conducting this study required researchers to adopt assumptions regarding the duration of patients from these drugs, which could affect the results.

“Bone and joint inflammation significantly reduces the quality of life due to devastating pain and limited mobility. It has been shown that obesity shortens life expectancy,” said Losin. “Offering these drugs to patients with osteoarthritis and obesity improves both measures.”